LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response.

Bone marrow-derived mesenchymal stem cells (MSC) have been shown to home into tumor tissues, where they promote tumor growth and suppress immune rejection. In this study, we tested whether MSCs engineered to express the immune stimulating factor LIGHT, a member of the TNF superfamily, could induce tumor regression. Using in vitro and in vivo migration assays, we found that LIGHT-expressing MSCs (MSC-L) displayed a strong tropism for tumor tissues. MSC-L treatment activated the LIGHT-signaling pathway, effectively organizing a potent antitumor immune response that stimulated an influx of T cells and inhibited tumor growth in vivo. CD4 T cells were found to play a role in the induction phase of the immune response, and CD8 T cells were shown to be essential for the effector phase. Together, our findings indicate that MSCs can effectively home into and deliver immune stimulating molecules to tumor tissues, thereby reversing the immune-suppressive environment, promoting antitumor immunity, and inhibiting tumor growth.

[1]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[2]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[3]  Hiroyuki Tomita,et al.  Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. , 2011, Cancer cell.

[4]  H. Schreiber,et al.  Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase , 2010, The Journal of experimental medicine.

[5]  J. Medin,et al.  Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. , 2010, Cancer research.

[6]  M. Greene,et al.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. , 2010, Cancer cell.

[7]  W. Woodward,et al.  Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast Cells , 2010, PloS one.

[8]  Cathrin Brisken,et al.  Epithelial‐Mesenchymal Transition‐Derived Cells Exhibit Multilineage Differentiation Potential Similar to Mesenchymal Stem Cells , 2010, Stem cells.

[9]  Z. Werb,et al.  Tumors as organs: complex tissues that interface with the entire organism. , 2010, Developmental cell.

[10]  Y. DeClerck,et al.  Bone marrow-derived mesenchymal stem cells and the tumor microenvironment , 2010, Cancer and Metastasis Reviews.

[11]  S. Raiden,et al.  Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-Like Profile , 2010, PloS one.

[12]  R. Romieu-Mourez,et al.  Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. , 2009, Blood.

[13]  D. Davies,et al.  Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. , 2009, Cancer research.

[14]  D. Bonnet,et al.  Isolation, culture, and differentiation potential of mouse marrow stromal cells. , 2008, Current protocols in stem cell biology.

[15]  H. Friess,et al.  VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma , 2008, British Journal of Cancer.

[16]  B. Quesnel Tumor dormancy and immunoescape   , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[17]  M. Yarmush,et al.  Bone Marrow‐Derived Mesenchymal Stem Cells Ameliorate Autoimmune Enteropathy Independently of Regulatory T Cells , 2008, Stem cells.

[18]  D. Martineau,et al.  Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. , 2008, Cancer research.

[19]  M. Schwaiger,et al.  TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. , 2008, Cancer cell.

[20]  yang-xin fu,et al.  Targeting tumors with LIGHT to generate metastasis-clearing immunity. , 2008, Cytokine & growth factor reviews.

[21]  W. Woodward,et al.  Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. , 2007, Cancer research.

[22]  A. Nauta,et al.  Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.

[23]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[24]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[25]  M. Kerin,et al.  Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells , 2007, Clinical Cancer Research.

[26]  Youjin Lee,et al.  Targeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases1 , 2007, The Journal of Immunology.

[27]  R. Weichselbaum,et al.  Induced sensitization of tumor stroma leads to eradication of established cancer by T cells , 2007, The Journal of experimental medicine.

[28]  A. Uccelli,et al.  Immunoregulatory function of mesenchymal stem cells , 2006, European journal of immunology.

[29]  S. Nadri,et al.  Murine mesenchymal stem cells isolated by low density primary culture system , 2006, Development, growth & differentiation.

[30]  M. Loeffler,et al.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.

[31]  Anoop P. Patel,et al.  Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. , 2006, Blood.

[32]  M. Raffeld,et al.  Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma , 2006, The Journal of experimental medicine.

[33]  H. Schreiber,et al.  The role of stroma in immune recognition and destruction of well-established solid tumors. , 2006, Current opinion in immunology.

[34]  J. Galipeau,et al.  Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. , 2006, Blood.

[35]  David Zurakowski,et al.  A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.

[36]  H. Schreiber,et al.  Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.

[37]  Youjin Lee,et al.  Priming of naive T cells inside tumors leads to eradication of established tumors , 2004, Nature Immunology.

[38]  F. Djouad,et al.  Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. , 2003, Blood.

[39]  Lindolfo da Silva Meirelles,et al.  Murine marrow‐derived mesenchymal stem cell: isolation, in vitro expansion, and characterization , 2003, British journal of haematology.

[40]  S. Granger,et al.  LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. , 2003, Cytokine & growth factor reviews.

[41]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[42]  Y. Zhai,et al.  LIGHT, a new member of the TNF superfamily. , 2002, Journal of biological regulators and homeostatic agents.

[43]  Osamu Yoshie,et al.  Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. , 2002, Immunity.

[44]  K. Tamada,et al.  The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. , 2001, The Journal of clinical investigation.

[45]  J. Bluestone,et al.  Reversal of Spontaneous Autoimmune Insulitis in Nonobese Diabetic Mice by Soluble Lymphotoxin Receptor , 2001, The Journal of experimental medicine.

[46]  G. Zhu,et al.  Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway , 2000, Nature Medicine.

[47]  L. Williams,et al.  Mice Lacking Expression of Secondary Lymphoid Organ Chemokine Have Defects in Lymphocyte Homing and Dendritic Cell Localization , 1999, The Journal of experimental medicine.

[48]  D. Gisselsson,et al.  Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  M. Soleimani,et al.  A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow , 2009, Nature Protocols.

[50]  K. Kang,et al.  Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. , 2009, Cytotherapy.

[51]  C. Ware,et al.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. , 1998, Immunity.